Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 8, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Left Atrial Appendage Closure Lacks Sufficient Evidence for Routine Use.

Mohammed Ruzieh1, Andrew J Foy2, John Mandrola3

  • 1Bluhm Cardiovascular Institute, Northwestern University, Feinberg School of Medicine, United States.

Thrombosis and Haemostasis
|May 6, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Reply.

The American journal of medicine·2026
Same author

Trial emulation of percutaneous left atrial appendage occlusion versus direct oral anticoagulants.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Safety of catheter ablation compared with antiarrhythmic drugs for atrial fibrillation: A systematic review and meta-analysis of randomized trials.

Heart rhythm·2026
Same author

Laryngospasm during pulsed field ablation: A sign of warning for a device-specific complication?

HeartRhythm case reports·2026
Same author

In adults at high risk for ventricular arrhythmia, treatment to increase potassium to high-normal levels improved a composite outcome.

Annals of internal medicine·2026
Same author

Impact of intravenous atropine bolus on eye pupil diameter and autonomic function in patients evaluated for cardioneuroablation.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2025
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Percutaneous left atrial appendage occlusion (pLAAO) shows promise for atrial fibrillation patients but current evidence is limited. Further research is needed to confirm its efficacy and safety compared to non-vitamin K antagonist oral anticoagulants (NOACs).

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Trials

Background:

  • Atrial fibrillation (AF) management often involves anticoagulation.
  • Percutaneous left atrial appendage occlusion (pLAAO) is emerging as an alternative to oral anticoagulants.
  • Non-vitamin K antagonist oral anticoagulants (NOACs) are standard therapy for stroke prevention in AF.

Purpose of the Study:

  • To critically evaluate the current evidence supporting pLAAO as an alternative to NOACs for AF patients.
  • To identify key limitations in existing clinical trial data for pLAAO.
  • To assess the justification for the growing enthusiasm surrounding pLAAO.

Main Methods:

  • Review and analysis of existing clinical trial data on pLAAO.
  • Examination of primary efficacy endpoints and their components.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

Related Experiment Videos

Last Updated: May 8, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

  • Assessment of statistical power for detecting key clinical events.
  • Evaluation of reported bleeding outcomes.

    • Main Results:

    • Some trials utilized wide non-inferiority margins, potentially inflating perceived efficacy.
    • Primary endpoints included factors not directly impacted by pLAAO, simplifying non-inferiority demonstration.
    • Limited statistical power exists to reliably detect differences in ischemic stroke or systemic embolism rates.
    • The reported bleeding advantage of pLAAO may be overstated.

    Conclusions:

    • The current evidence base does not fully support the widespread adoption of pLAAO over NOACs.
    • Methodological limitations in trials necessitate cautious interpretation of pLAAO's benefits.
    • Further robust clinical trials are required to definitively establish the role of pLAAO in AF management.